| abstract |
The present invention is directed to imidazolin-5-one derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, and liver related disorders. Such compounds are represented by formula (I) as follows: n n n n n n n n n n n n wherein R 1 , R 2 , R 3 , R 4 , R 5 , m, n, and n n n n n n n n n n n n n n are defined herein. |